A Novel Antibody Targeting Tau Phosphorylated at Serine 235 Detects Neurofibrillary Tangles.

Alzheimer's disease is characterized by two main pathological hallmarks in the human brain: the extracellular deposition of amyloid-β as plaques and the intracellular accumulation of the hyperphosphorylated protein tau as neurofibrillary tangles (NFTs). Phosphorylated tau (p-tau) specific-antibodies and silver staining have been used to reveal three morphological stages of NFT formation: pre-NFTs, intraneuronal NFTs (iNFTs), and extraneuronal NFTs (eNFTs). Here we characterize a novel monoclonal antibody, RN235, which is specific for tau phosphorylated at serine 235, and detects iNFTs and eNFTs in brain tissue, suggesting that phosphorylation at this site is indicative of late stage changes in tau.

[1]  A. Van der Jeugd,et al.  Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model , 2017, Brain : a journal of neurology.

[2]  Xiaomin Song,et al.  Co-immunoprecipitation with Tau Isoform-specific Antibodies Reveals Distinct Protein Interactions and Highlights a Putative Role for 2N Tau in Disease , 2016, The Journal of Biological Chemistry.

[3]  M. Strong,et al.  Thr175-phosphorylated tau induces pathologic fibril formation via GSK3β-mediated phosphorylation of Thr231 in vitro , 2015, Neurobiology of Aging.

[4]  Neha S Gandhi,et al.  Molecular dynamics simulation of the phosphorylation‐induced conformational changes of a tau peptide fragment , 2014, Proteins.

[5]  I. Landrieu,et al.  Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline‐rich region of the disordered Tau protein , 2012, Proteins.

[6]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[7]  I. Landrieu,et al.  Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  W. Noble,et al.  Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. , 2009, Trends in molecular medicine.

[9]  Jürgen Götz,et al.  Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia , 2008, Proceedings of the National Academy of Sciences.

[10]  H. Paudel,et al.  Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. , 2006, Biochemistry.

[11]  J. Cho,et al.  Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3β (GSK3β) plays a critical role in regulating tau's ability to bind and stabilize microtubules , 2003, Journal of neurochemistry.

[12]  J. Götz,et al.  Extracellular Vesicles Containing P301L Mutant Tau Accelerate Pathological Tau Phosphorylation and Oligomer Formation but Do Not Seed Mature Neurofibrillary Tangles in ALZ17 Mice. , 2016, Journal of Alzheimer's disease : JAD.

[13]  Bradley T. Hyman,et al.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease , 2014, Acta Neuropathologica.